Published in Cytopathology on October 01, 1999
The diagnosis and management of pre-invasive breast disease: the role of new diagnostic techniques. Breast Cancer Res (2003) 1.00
Determination of HER-2 status on FNAC material from breast carcinomas using in situ hybridization with dual chromogen visualization with silver enhancement (dual SISH). Cytojournal (2010) 0.90
Liquid based material from fine needle aspirates from breast carcinomas offers the possibility of long-time storage without significant loss of immunoreactivity of estrogen and progesterone receptors. Cytojournal (2010) 0.83
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res (2000) 4.66
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2001) 4.13
[Second Opinion Consult Clinic for Surgical Oncology in the Daniel den Hoed Clinic: analysis of the first 245 patients]. Ned Tijdschr Geneeskd (1999) 2.56
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000) 2.09
A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. J Clin Pathol (1997) 1.76
Regional metastasis in head and neck squamous cell carcinoma: revised value of US with US-guided FNAB. Radiology (1996) 1.59
Ultrasound-guided aspiration biopsy for detection of nonpalpable axillary node metastases in breast cancer patients: new diagnostic method. World J Surg (1997) 1.48
Antibodies to components of neutrophil cytoplasm: a new diagnostic tool in patients with Wegener's granulomatosis and systemic vasculitis. Q J Med (1988) 1.47
[Endometriosis of the rectum]. Ned Tijdschr Geneeskd (1993) 1.37
The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer (1996) 1.34
Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry (1993) 1.33
Diagnostic value of anti-neuronal antibodies for paraneoplastic disorders of the nervous system. J Neurol Neurosurg Psychiatry (1990) 1.13
Differential regulation of breast tumor cell proliferation by stromal fibroblasts of various breast tissue sources. Int J Cancer (1996) 1.13
Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. Eur J Cancer (1998) 1.13
Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol (1998) 1.12
Contribution of renal biopsy data in predicting outcome in lupus nephritis. Analysis of 116 patients. Arthritis Rheum (1990) 1.11
Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer (2001) 1.08
Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer. Int J Cancer (1992) 1.05
The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer (1997) 1.05
Stromal influences on breast cancer cell growth. Br J Cancer (1992) 1.03
Neurone-specific enolase and S-100: new markers for delineating the innervation of the respiratory tract in man and other mammals. Thorax (1983) 1.00
The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study. Eur J Cancer (1993) 0.98
The value of ultrasound with ultrasound-guided fine-needle aspiration biopsy compared to computed tomography in the detection of regional metastases in the clinically negative neck. Int J Radiat Oncol Biol Phys (1998) 0.97
Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry. Am J Pathol (1994) 0.97
Receptors for hormones and growth factors and (onco)-gene amplification in human ovarian cancer. Int J Cancer (1992) 0.97
Angiosarcoma of the breast following lumpectomy, axillary lymph node dissection, and radiotherapy for primary breast cancer: three case reports and a review of the literature. Int J Radiat Oncol Biol Phys (1993) 0.95
Quality control of immunocytochemical staining of effusions using a standardized method of cell processing. Acta Cytol (1996) 0.95
Expression of estrogen, progesterone and epidermal growth factor receptors in primary and metastatic breast cancer. Int J Cancer (1995) 0.94
Discrepancy between second and first opinion in surgical oncological patients. Eur J Surg Oncol (2005) 0.93
Simultaneous immunoenzyme staining of vimentin and cytokeratins with monoclonal antibodies as an aid in the differential diagnosis of malignant mesothelioma from pulmonary adenocarcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol (1986) 0.93
Influence of fixation and decalcification on the immunohistochemical staining of cell-specific markers in paraffin-embedded human bone biopsies. J Histochem Cytochem (1985) 0.92
Immunohistochemical study of the BCAR1/p130Cas protein in non-malignant and malignant human breast tissue. Int J Biol Markers (2001) 0.91
Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication. Cancer (1994) 0.91
Antineuronal antibodies in patients with neurologic complications of primary Sjögren's syndrome. Neurology (1993) 0.91
Loss of imprinting of IGF2 and not H19 in breast cancer, adjacent normal tissue and derived fibroblast cultures. FEBS Lett (1998) 0.91
Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer. J Steroid Biochem Mol Biol (1990) 0.90
Expression of the gene encoding growth hormone in the human mammary gland. J Clin Endocrinol Metab (1995) 0.89
Prognostic value of CD44 variant expression in primary breast cancer. Int J Cancer (1999) 0.89
Expression of cytokeratins and vimentin in epithelial cells of normal and pathologic thyroid tissue. Virchows Arch A Pathol Anat Histopathol (1987) 0.88
Anti-neuronal antibodies in paraneoplastic neurological disorders with small-cell lung carcinoma. Clin Neurol Neurosurg (1990) 0.88
Ki-67 staining in histological subtypes of breast carcinoma and fine needle aspiration smears. J Clin Pathol (1991) 0.88
Genetic alterations in ovarian borderline tumours and ovarian carcinomas. Eur J Obstet Gynecol Reprod Biol (1999) 0.86
Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int J Cancer (1996) 0.85
Cytokine-regulated urokinase-type-plasminogen-activator (uPA) production by human breast fibroblasts in vitro. Breast Cancer Res Treat (1999) 0.85
High prevalence of codon 213Arg-->Stop mutations of the TP53 gene in human ovarian cancer in the southwestern part of The Netherlands. Int J Cancer (1998) 0.85
Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours. Br J Cancer (1996) 0.84
Axillary nodal metastases from an occult primary consistent with breast carcinoma. Br J Surg (1993) 0.84
Controlled introduction of the sentinel node biopsy in breast cancer in a multi-centre setting: the role of a coordinator for quality control. Eur J Surg Oncol (2000) 0.82
Carcinoma of unknown primary: identification of a treatable subset? Ann Oncol (1990) 0.82
Altered expression of p53 and its regulated proteins in phyllodes tumours of the breast. J Pathol (1999) 0.81
Postinfantile giant cell hepatitis in a patient with multiple autoimmune features. Am J Gastroenterol (1985) 0.81
Transforming growth factor beta secretion from primary breast cancer fibroblasts. Mol Cell Endocrinol (1995) 0.80
Reasons for failure to identify positive sentinel nodes in breast cancer patients with significant nodal involvement. Eur J Surg Oncol (2006) 0.80
Molecular genetic evidence for unifocal origin of advanced epithelial ovarian cancer and for minor clonal divergence. Br J Cancer (1995) 0.80
A rapid and simple hapten conjugation method for monoclonal antibodies to be used in immunoenzyme single and double staining procedures. J Immunol Methods (1987) 0.79
Systemic and anti-neuronal auto-antibodies in patients with paraneoplastic neurological disease. J Neurol (1996) 0.79
The value of immunohistochemistry in patients with poorly differentiated adenocarcinomas and undifferentiated carcinomas of unknown primary. J Cancer Res Clin Oncol (1996) 0.78
Cervical cancer metastasising to the breast: report of two cases. Eur J Surg (1993) 0.77
Quantification of area percentage of immunohistochemical staining by true color image analysis with application of fixed thresholds. Anal Quant Cytol Histol (1994) 0.77
Immunohistochemical analysis of the cerebrospinal fluid for carcinomatous and lymphomatous leptomeningitis. Br J Cancer (1990) 0.77
Serous otitis media and immunological reactions in the middle ear mucosa. Acta Otolaryngol (1989) 0.77
Leucocytoclastic vasculitis as presenting feature of primary Sjögren's syndrome. Clin Rheumatol (1994) 0.77
Relation between serological data at the time of biopsy and renal histology in lupus nephritis. Rheumatol Int (1991) 0.76
[Bronchial carcinoma with secondary amyloidosis as a cause of nephrotic syndrome]. Ned Tijdschr Geneeskd (1982) 0.76
Hyperbilirubinaemia in patients treated with recombinant human interleukin-2 (rIL-2) Br J Cancer (1990) 0.75
Anti-neuronal antibodies in Sjögren's syndrome and in paraneoplastic neurological disease. Lancet (1994) 0.75
Influence of hydrolysis products of aqua(1,1-bis(aminomethyl)cyclohexane)sulfatoplatinum(II) on toxicity in rats. Cancer Lett (1984) 0.75
Monoclonal antibodies in the histopathological diagnosis of non-Hodgkin lymphomas. Neth J Med (1985) 0.75
Phase II study of oral administration of etoposide for patients with well- and moderately-differentiated adenocarcinomas of unknown primary site. Ann Oncol (1993) 0.75
Phase I studies of rodorubicin single bolus and daily times five, once every three weeks in patients with advanced solid tumors. Eur J Cancer Clin Oncol (1989) 0.75
Thyroglossal cysts in patients over 30 years of age. Int J Oral Maxillofac Surg (1987) 0.75
Immunocytochemical staining of effusions; an external quality control study in The Netherlands. Cytopathology (1997) 0.75
Post-irradiation angiosarcoma of the greater omentum. Eur J Surg Oncol (1989) 0.75
Quantification of relative area of pS2 immunohistochemical staining and epithelial percentage in breast carcinomas: the effect of the latter on the interpretation of a cytosolic pS2 assay. Mod Pathol (1995) 0.75
[Artificial rearing of young rats with rat's milk. Technic of milking and feeding]. Z Versuchstierkd (1971) 0.75